Home › Prostate Cancer › NCT05478694

Outcomes of Focal Ablation for Prostate Cancer

Prospective Single Institutional Study Evaluating the Outcomes for Patients Undergoing Ablative Therapies in the Management of Clinically Localized Prostate Cancer in the Primary and Salvage Setting

Who can join

Ages 18 to 90 · Men

Inclusion Criteria:

* Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy
* Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease
* Age 18-90 years.
* Life expectancy \> 1 year
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Anatomic abnormalities that do not allow for focal ablation
* Evidence of non-organ confined disease that is not feasible for ablation
* Has active urinary traction infection

About the study

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

Sponsor: University of Texas Southwestern Medical Center · Participants: 225 · Started: Feb 1, 2023

Contact the study team

• Sonobia Garrett · Phone: 214/645-8482

Official record on ClinicalTrials.gov — NCT05478694

Locations in the U.S.

Conditions

• Prostate Cancer

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.